Gastrointestinal Stromal Tumors: Our Ten-Year Experience of a Single-Center Tertiary Hospital.
GIST
Greece
case series
gastrointestinal stromal tumors
review
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
13 Aug 2023
13 Aug 2023
Historique:
received:
15
07
2023
revised:
31
07
2023
accepted:
11
08
2023
medline:
25
8
2023
pubmed:
25
8
2023
entrez:
25
8
2023
Statut:
epublish
Résumé
Gastrointestinal stromal tumors (GISTs) are the most frequent mesenchymal neoplasms of the gastrointestinal tract. They have variable clinical presentation, prognosis, and molecular characteristics. Here, we present the results of our retrospective study including patients operated on for GIST during the last decade. All the patients who underwent GIST resection during the decade 2008-2018 were included in the study. The diagnosis was based on the pathology report. All the data were collected and analyzed statistically using the Statistical Package for Social Science v25.0. Finally, after having applied the proper search terms, a comprehensive review of articles published in the Medline database was held. Thirty-two patients (sixteen women) were included in the study with a mean age of 69.6 years old (SD = 13.9). Twenty-one patients had a GIST in the stomach, eight in the small intestine, and three had an extra GIST. Of the 29 patients contacted, 21 were alive with a mean survival time of 74.3 months (SD = 49.6 months, min: 3.0 months, max: 161.0 months), whereas eight patients passed away. Finally, 13 patients were treated with tyrosine kinase inhibitors (TKIs) of whom only one died, while 9 patients passed away from those treated with surgery alone ( Our results were in concordance with the existing data in the literature. GISTs require patient-based therapeutical management depending on the histology of the tumors. Gastric tumors present a better prognosis than those localized in the intestine, while the use of TKIs has led to an improvement in patient survival rate.
Sections du résumé
BACKGROUND
BACKGROUND
Gastrointestinal stromal tumors (GISTs) are the most frequent mesenchymal neoplasms of the gastrointestinal tract. They have variable clinical presentation, prognosis, and molecular characteristics. Here, we present the results of our retrospective study including patients operated on for GIST during the last decade.
METHODS
METHODS
All the patients who underwent GIST resection during the decade 2008-2018 were included in the study. The diagnosis was based on the pathology report. All the data were collected and analyzed statistically using the Statistical Package for Social Science v25.0. Finally, after having applied the proper search terms, a comprehensive review of articles published in the Medline database was held.
RESULTS
RESULTS
Thirty-two patients (sixteen women) were included in the study with a mean age of 69.6 years old (SD = 13.9). Twenty-one patients had a GIST in the stomach, eight in the small intestine, and three had an extra GIST. Of the 29 patients contacted, 21 were alive with a mean survival time of 74.3 months (SD = 49.6 months, min: 3.0 months, max: 161.0 months), whereas eight patients passed away. Finally, 13 patients were treated with tyrosine kinase inhibitors (TKIs) of whom only one died, while 9 patients passed away from those treated with surgery alone (
CONCLUSIONS
CONCLUSIONS
Our results were in concordance with the existing data in the literature. GISTs require patient-based therapeutical management depending on the histology of the tumors. Gastric tumors present a better prognosis than those localized in the intestine, while the use of TKIs has led to an improvement in patient survival rate.
Identifiants
pubmed: 37623504
pii: jpm13081254
doi: 10.3390/jpm13081254
pmc: PMC10455766
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Hum Pathol. 2002 May;33(5):478-83
pubmed: 12094372
Am J Clin Pathol. 1995 Jan;103(1):41-7
pubmed: 7817943
Semin Diagn Pathol. 2006 May;23(2):70-83
pubmed: 17193820
Ann Oncol. 2022 Jan;33(1):20-33
pubmed: 34560242
Int J Cancer. 2005 Nov 1;117(2):289-93
pubmed: 15900576
Kurume Med J. 2001;48(3):233-6
pubmed: 11680940
Eur J Cancer. 2005 Dec;41(18):2868-72
pubmed: 16293410
Virchows Arch. 2001 Jan;438(1):1-12
pubmed: 11213830
Eur Radiol. 2003 Jul;13(7):1669-78
pubmed: 12835984
Lancet Oncol. 2009 Nov;10(11):1045-52
pubmed: 19793678
Oncology (Williston Park). 2012 Mar;26(3):264, 309
pubmed: 22545310
J Laparoendosc Adv Surg Tech A. 2012 Oct;22(8):758-63
pubmed: 22957924
N Engl J Med. 2001 Apr 5;344(14):1052-6
pubmed: 11287975
J Gastrointest Oncol. 2017 Jun;8(3):466-473
pubmed: 28736634
Science. 1998 Jan 23;279(5350):577-80
pubmed: 9438854
Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):298-302
pubmed: 25277795
JAMA. 2012 Mar 28;307(12):1265-72
pubmed: 22453568
J Cancer. 2019 Oct 6;10(23):5785-5792
pubmed: 31737115
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv68-iv78
pubmed: 29846513
J Clin Oncol. 2003 Dec 1;21(23):4342-9
pubmed: 14645423
Anticancer Res. 2020 Jan;40(1):435-441
pubmed: 31892598
Cancer Sci. 2006 Feb;97(2):127-32
pubmed: 16441423
Eur J Cancer. 2003 Sep;39(14):2012-20
pubmed: 12957455
Cancer. 2005 Feb 15;103(4):821-9
pubmed: 15648083
Surg Endosc. 2022 Sep;36(9):6841-6850
pubmed: 35048188
Cancer Imaging. 2005 Dec 15;5:150-6
pubmed: 16361144
Am J Surg Pathol. 1983 Sep;7(6):507-19
pubmed: 6625048
J Gastrointest Surg. 2020 Dec;24(12):2714-2721
pubmed: 31823317
Ann Ital Chir. 2019;90:31-40
pubmed: 30942768
Hum Pathol. 2002 May;33(5):459-65
pubmed: 12094370
Transl Oncol. 2020 Oct;13(10):100812
pubmed: 32619820
Lancet. 2013 Jan 26;381(9863):295-302
pubmed: 23177515
Ann R Coll Surg Engl. 2014 Jan;96(1):96E-100E
pubmed: 24417854
World J Gastroenterol. 2005 Feb 21;11(7):1052-5
pubmed: 15742414
Lancet. 2009 Mar 28;373(9669):1097-104
pubmed: 19303137
Lancet Oncol. 2020 Jul;21(7):935-946
pubmed: 32615108
Am J Pathol. 1998 May;152(5):1259-69
pubmed: 9588894